Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial

IF 2.5 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Mingming Wang, Jianshu Chen, Miaomiao Qi, Runmin Sun, Zhangyou Long, Quanbin Su, Yanhong Mou, Hengxia Liu, Qiongying Wang, Qiang Wu, Xiaowei Zhang, Jing Yu
{"title":"Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial","authors":"Mingming Wang,&nbsp;Jianshu Chen,&nbsp;Miaomiao Qi,&nbsp;Runmin Sun,&nbsp;Zhangyou Long,&nbsp;Quanbin Su,&nbsp;Yanhong Mou,&nbsp;Hengxia Liu,&nbsp;Qiongying Wang,&nbsp;Qiang Wu,&nbsp;Xiaowei Zhang,&nbsp;Jing Yu","doi":"10.1111/jch.70145","DOIUrl":null,"url":null,"abstract":"<p>This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended-release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). Patients were randomized to two groups. After 6-month, the IIEF-15 total score (ITS) of sexual function significantly improved in Group A+C (<i>p</i> = 0.015), including intercourse satisfaction (IS) (<i>p</i> = 0.003), orgasmic function (OF) (<i>p</i> = 0.021), and overall satisfaction (OS) (<i>p</i> = 0.019), while erectile function (EF) (<i>p</i> = 0.081) and sexual desire (SD) (<i>p</i> = 0.08) were unchanged. In contrast, the ITS was decreased (<i>p</i> = 0.008), including EF (<i>p</i> = 0.005), IS (<i>p</i> = 0.048), SD (<i>p</i> = 0.003), and OS (<i>p</i> = 0.010), but OF remained unchanged (<i>p</i> = 0.076) in Group A+B. Between-group comparisons confirmed significant differences across IIEF-15 domains (all <i>p</i> &lt; 0.05). Compared to baseline, office systolic BP (OSBP), office diastolic BP (ODBP), nighttime average SBP (nSBP), and nighttime average DBP (nDBP) were significantly reduced at 6 months in two groups (all <i>p</i> &lt; 0.05). Although nSBP fall (nSBPF) (<i>p</i> = 0.010) and nDBP fall (nDBPF) (<i>p</i> = 0.002) significantly increased in Group A+C. In Group A+C, the nighttime-daytime BP fall ratio of SBP was 1.04 (0.45, 1.70) and that of DBP was 1.13 (0.38, 1.44) after treatment, with a median value &gt; 1, indicating that nBP fall after treatment was greater than dBP fall. Compared to Group A+B, ODBP (difference = −4.00 mmHg, 95% CI [−7.64, −0.36], <i>p</i> = 0.032), daytime average DBP (difference = −5.47 mmHg, 95% CI [−10.05, −0.79], <i>p</i> = 0.023) and 24-h average DBP (difference = −5.77 mmHg, 95% CI [−10.31, −1.24], <i>p</i> = 0.014) decreased more significantly in Group A+C, nDBPF increased significantly (difference = 4.99 mmHg, 95% CI [0.04, 9.93], <i>p</i> = 0.048), and the decrease in the nighttime-daytime BP fall ratio of SBP and DBP was higher (<i>p</i> &lt; 0.05). It was concluded that combined antihypertension of allisartan isoproxil with amlodipine besylate tablets improved sexual function in male hypertensive patients in terms of the ITS, IS, OF, and OS, but there was no significant improvement in EF and SD. Both combined antihypertensive regimens were effective in lowering BP, but allisartan isoproxil combined with amlodipine besylate tablets demonstrated more advantageous in lowering DBP and nBP.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"27 9","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12445202/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Hypertension","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jch.70145","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended-release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). Patients were randomized to two groups. After 6-month, the IIEF-15 total score (ITS) of sexual function significantly improved in Group A+C (p = 0.015), including intercourse satisfaction (IS) (p = 0.003), orgasmic function (OF) (p = 0.021), and overall satisfaction (OS) (p = 0.019), while erectile function (EF) (p = 0.081) and sexual desire (SD) (p = 0.08) were unchanged. In contrast, the ITS was decreased (p = 0.008), including EF (p = 0.005), IS (p = 0.048), SD (p = 0.003), and OS (p = 0.010), but OF remained unchanged (p = 0.076) in Group A+B. Between-group comparisons confirmed significant differences across IIEF-15 domains (all p < 0.05). Compared to baseline, office systolic BP (OSBP), office diastolic BP (ODBP), nighttime average SBP (nSBP), and nighttime average DBP (nDBP) were significantly reduced at 6 months in two groups (all p < 0.05). Although nSBP fall (nSBPF) (p = 0.010) and nDBP fall (nDBPF) (p = 0.002) significantly increased in Group A+C. In Group A+C, the nighttime-daytime BP fall ratio of SBP was 1.04 (0.45, 1.70) and that of DBP was 1.13 (0.38, 1.44) after treatment, with a median value > 1, indicating that nBP fall after treatment was greater than dBP fall. Compared to Group A+B, ODBP (difference = −4.00 mmHg, 95% CI [−7.64, −0.36], p = 0.032), daytime average DBP (difference = −5.47 mmHg, 95% CI [−10.05, −0.79], p = 0.023) and 24-h average DBP (difference = −5.77 mmHg, 95% CI [−10.31, −1.24], p = 0.014) decreased more significantly in Group A+C, nDBPF increased significantly (difference = 4.99 mmHg, 95% CI [0.04, 9.93], p = 0.048), and the decrease in the nighttime-daytime BP fall ratio of SBP and DBP was higher (p < 0.05). It was concluded that combined antihypertension of allisartan isoproxil with amlodipine besylate tablets improved sexual function in male hypertensive patients in terms of the ITS, IS, OF, and OS, but there was no significant improvement in EF and SD. Both combined antihypertensive regimens were effective in lowering BP, but allisartan isoproxil combined with amlodipine besylate tablets demonstrated more advantageous in lowering DBP and nBP.

Abstract Image

两种基于阿利沙坦异proxil的降压治疗对男性高血压患者性功能和血压的影响:一项单中心、开放标签、随机对照试验
本研究对130例男性原发性高血压(EH)患者应用异丙酸艾沙坦联合苯磺酸氨氯地平片(A+C组)或琥珀酸美托洛尔缓释片(A+B组)对性功能和夜间血压(nBP)的影响进行评价。患者随机分为两组。6个月后,A+C组性功能的IIEF-15总分(ITS)显著提高(p = 0.015),其中性交满意度(IS) (p = 0.003)、性高潮功能(of) (p = 0.021)、总体满意度(OS) (p = 0.019),勃起功能(EF) (p = 0.081)、性欲(SD) (p = 0.08)无变化。相比之下,A+B组ITS降低(p = 0.008),包括EF (p = 0.005)、IS (p = 0.048)、SD (p = 0.003)和OS (p = 0.010),但OF保持不变(p = 0.076)。组间比较证实IIEF-15域之间存在显著差异(均p < 0.05)。与基线相比,两组患者6个月时收缩压(OSBP)、舒张压(ODBP)、夜间平均收缩压(nSBP)和夜间平均舒张压(nDBP)均显著降低(均p < 0.05)。A+C组nSBP下降(nSBPF) (p = 0.010)和nDBP下降(nDBPF) (p = 0.002)均显著升高。A+C组治疗后夜间-日间收缩压下降比为1.04(0.45,1.70),舒张压下降比为1.13(0.38,1.44),中位数为>.1,说明治疗后nBP下降大于舒张压下降。与A组+ B相比,ODBP(差异= -4.00毫米汞柱,95%可信区间[-7.64,-0.36],p = 0.032),白天平均菲律宾(差异= -5.47毫米汞柱,95%可信区间[-10.05,-0.79],p = 0.023)和24小时平均菲律宾(差异= -5.77毫米汞柱,95%可信区间[-10.31,-1.24],p = 0.014)下降更显著的A + C组,nDBPF显著增加(差异= 4.99毫米汞柱,95%可信区间[0.04,9.93],p = 0.048),和减少nighttime-daytime BP下降的比例SBP和菲律宾较高(p < 0.05)。综上所述,异丙嗪阿利沙坦联合苯磺酸氨氯地平片联合降压可改善男性高血压患者的性功能,包括ITS、IS、of和OS,但EF和SD无明显改善。两种联合降压方案均能有效降低血压,但阿利沙坦异丙酯联合苯磺酸氨氯地平片在降低DBP和nBP方面更有优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Hypertension
Journal of Clinical Hypertension PERIPHERAL VASCULAR DISEASE-
CiteScore
5.80
自引率
7.10%
发文量
191
审稿时长
4-8 weeks
期刊介绍: The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves internists, cardiologists, nephrologists, endocrinologists, hypertension specialists, primary care practitioners, pharmacists and all professionals interested in hypertension by providing objective, up-to-date information and practical recommendations on the full range of clinical aspects of hypertension. Commentaries and columns by experts in the field provide further insights into our original research articles as well as on major articles published elsewhere. Major guidelines for the management of hypertension are also an important feature of the Journal. Through its partnership with the World Hypertension League, JCH will include a new focus on hypertension and public health, including major policy issues, that features research and reviews related to disease characteristics and management at the population level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信